Pipeline

Advancing the art and science of imaging

We are developing next generation imaging agents to enhance the accuracy, reliability and safety of diagnostic imaging. With a strong track record in product discovery and commercialization, we have developed two internally-discovered imaging agents that are currently in clinical stages.

Our agents in development are primarily used in diagnostic imaging for heart disease, the leading cause of death for both women and men in the United States and worldwide. According to the American Heart Association (AHA), an estimated 85.6 million American adults, greater than one in three, have one or more types of heart disease. Our pipeline agents include:

  • Flurpiridaz F 18, a myocardial perfusion imaging (MPI) agent, which could significantly improve the evaluation of coronary artery disease (CAD)
  • LMI 1195, a cardiac neuronal agent (CNA) which could allow for better identification of patients at risk of sudden cardiac death (SCD)

We believe our products in development have the potential to significantly enhance current imaging modalities and fulfill unmet diagnostic medical imaging needs to:

  • Detect disease earlier
  • Make differentiated therapeutic decisions
  • Provide more tailored treatment
  • Reduce the need for additional testing and invasive procedures
  • Reduce cost burden to healthcare system

 

Flurpiridaz F 18

Positron emission tomography (PET) MPI

DiscoveryPreclinicalPhase 1Phase 2Phase 3

 LMI 1195 (Cardiac Neuronal Agent)

Sympathetic nervous system imaging for risk of heart failure/sudden death

DiscoveryPreclinicalPhase 1Phase 2Phase 3